Advanced Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, Leptomeningeal Metastasis
Conditions
Keywords
Breast cancer, HER2, Brain metastases, Metastatic, unresectable, pretreated
Brief summary
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial
Detailed description
Pretreated, unresectable locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-positive or HER2-low expressing breast cancer (BC) with untreated or treated brain metastases (BMs) or leptomeningeal carcinomatosis (LMC).
Interventions
DRUGTrastuzumab deruxtecan
After having confirmed eligibility and entered into the clinical trial, patients will be treated with trastuzumab deruxtecan (DS-8201a) at 5.4 mg/Kg administered as an intravenous (IV) infusion on Day of 21-day cycle (Q3W), initially for at least 90 minutes, then, if there is no infusion-related reaction, for a minimum of 30 minutes. In patients with hormone receptor (HR)-positive status (estrogen receptor \[ER\] and/or progesterone receptor \[PgR\]) administration of endocrine therapy is not allowed. In patients allocated in study cohort 5, administration of intrathecal therapy is not allowed
Sponsors
Daiichi Sankyo
MedSIR
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This is a multicenter, international, open-label, single-arm, multicohort, two-stage optimal Simon's design, phase II clinical trial. After confirmed eligibility, patients will be assigned to one of the following five study cohorts: * Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.); * Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM; * Cohort 3: HER2-positive BC with progressing BMs after local treatment; * Cohort 4: HER2-low expressing BC with progressing BMs after local treatment; * Cohort 5: HER2-positive or HER2-low expressing BC with LMC
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed Informed Consent Form (ICF) prior to participation in any study-related activities. 2. Male or female patients ≥ 18 years at the time of signing ICF. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 for Cohorts 1 to 4 and 0-2 for cohort 5. 4. Life expectancy ≥ 12 weeks. 5. Histologically confirmed invasive breast cancer based on local testing on the most recent analyzed biopsy of the following breast cancer (BC) subtypes per 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) criteria: * Cohort 1 and 3: HER2 positive status * Cohort 4: HER2-low expressing status * Cohort 2 and 5: both HER2 positive and HER2-low expressing status Note 1: According to the 2018 ASCO-CAP guidelines, HER2- positive status is defined as HER2 immunohistochemistry (IHC) 3+, in situ hybridization (ISH) ≥ 2.0, or average HER2 copy number ≥ 6.0 signals. HER2-low expressing status defined as IHC 2+ / ISH-negative or IHC 1+ (ISH-negative or untested). Note 2: Central confirmation of HER2 is not required for study entry. However, tissue blocks, or slides, must be submitted to confirm BC subtype by a Sponsor-designated central laboratory retrospectively. 6. Unresectable locally advanced or metastatic disease documented by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent. 7. At least one brain lesion needed to be measurable (≥10 mm on T1-weighted, gadolinium-enhanced MRI) (study cohorts 2 to 4) or leptomeningeal carcinomatosis (LMC) with positive cerebrospinal fluid (CSF) cytology (study cohort 5). * Study cohort 1: History of BM that are non-progressing after WBRT and/or SRS and or surgery. * Study cohort 2: Presence of asymptomatic BM without clinical requirement for local intervention (WBRT and/or SRS and/or surgery). * Study cohorts 3 and 4: Evidence of new and/or progressive BM following previous WBRT and/or SRS and/or surgery. * Study cohort 5: Evidence of LMC with positive CSF cytology. 8. Previous treatments: * For HER2-positive patients have been previously treated with a taxane and at least one HER2-targeted therapy in the advanced scenario. * For HER2-low-expressing patients that also are endocrine receptor negative must have been previously treated with at least one chemotherapy regimen. If endocrine receptor positive, patients must have been previously treated with at least one chemotherapy and one endocrine regimen in the metastatic setting. 9. Patients must agree to collection of blood samples at the time of inclusion, at cycle 2 of treatment, and upon progression or study termination. Note: In study cohort 5: Patients must agree to perform spinal taps or must be willing to have an Ommaya reservoir placed for CSF assessment, at baseline, every three weeks for 12 weeks (corresponding to the first 5 cycles of treatment) and every six weeks thereafter. 10. Willingness and ability to provide tumor biopsy (if feasible) from metastatic lesions or breast primary tumor both at the time of the inclusion and after disease progression in order to perform exploratory studies. Note: If feasible, patients should provide a tissue sample at baseline from metastases amenable to biopsy (at sites of locoregional recurrence \[skin, chest wall, breast or lymph nodes\], or distant recurrence \[bone, liver, lung or abdomen\]) or as alternative from breast primary tumor, that will be obtained between progression to the prior regimen and inclusion in the study. Patients for whom tissue sample cannot be obtained (e.g., non-measurable disease, inaccessible tumor or subject safety concern) may submit an archived metastatic tumor specimen only upon agreement from the Sponsor. If feasible, an additional tissue sample should be collected at the end of treatment visit for patients who discontinue treatment due to disease progression. 11. Patients should have left ventricular ejection fraction (LVEF) ≥ 50% by either an echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before enrolment. 12. Adequate hematologic and organ function within 14 days before the first study treatment on Day 1 of Cycle 1, defined by the following: • Hematological: White blood cell (WBC) count 3 3.0 x 109/L, absolute neutrophil count (ANC) 3 1.5 x 109/L, platelet count 3 100.0 x109/L, and hemoglobin 3 9.0 g/dL. (Platelet, red blood cell transfusion as well as G-CSF administration are not allowed within 1 week of screening assessments). Hepatic: Bilirubin ≤ 1.5 times the upper limit of normal (× ULN) (\< 3 x ULN in the case of documented Gilbert's disease and/or liver metastases); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 × ULN (in the case of liver metastases ≤ 5 × ULN); alkaline phosphatase (ALP) ≤ 2 × ULN (≤ 5 × ULN in the case of liver and/or bone metastases ≤ 5 × ULN), serum albumin 3 2.5 g/dL • Renal: Serum creatinine £ 1.5 × ULN or creatinine clearance ≥ 30 mL/min based on Cockcroft-Gault equation (\*Cockcroft-Gault equation: (\[{140 - age in years} × {ACTUAL WEIGHT in kg}\] divided by \[{72 × serum creatinine in mg/dL} multiplied by 0.85 if female\])) Coagulation: International Normalized Ratio (INR)/Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN (except for patients receiving anticoagulation therapy). Note: Patients receiving heparin treatment should have an aPTT) between 1.5 and 2.5 × ULN (or patient value before starting heparin treatment). Patients receiving coumarin derivatives should have an INR between 2.0 and 3.0 assessed in two consecutive measurements one to four days apart. Patients should be on a stable anticoagulant regimen. 13. Has adequate treatment washout period before enrollment, as indicated: 1. Major surgery: \> 4 weeks; 2. Radiation therapy: \> 4 weeks (palliative stereotactic radiation therapy to other areas ≥ 2 weeks); 3. Anticancer systemic treatment (including immunotherapy, retinoid therapy, hormonal therapy): ≥ 3 weeks (≥ 2 weeks or 5 half-lives, whichever is longer, for small-molecule targeted agents such as 5-fluorouracil-based agents, folinate agents, weekly paclitaxel; ≥ 6 weeks for nitrosureas or mitomycin C); 4. Antibody based anti-cancer therapy:≥ 4 weeks; 5. Chloroquine/Hydroxychloroquine\>14 days 14. Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤1 as determined by the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v.5.0 (except for alopecia or other toxicities). Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee (e.g., Grade 2 chemotherapy-induced neuropathy). 15. Male and female subjects of reproductive/childbearing potential must agree to use a highly effective form of contraception or avoid intercourse during and upon completion of the study and for at least 7 months for females and 4 months for males after the last dose of study drug. Methods considered as highly effective methods of contraception include: * Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: i. Oral ii. Intravaginal iii. Transdermal * Progestogen-only hormonal contraception associated with inhibition of ovulation: iv. Oral v. Injectable vi. Implantable * Intrauterine device (IUD) * Intrauterine hormone-releasing system (IUS) * Bilateral tubal occlusion * Vasectomized partner * Complete sexual abstinence defined as refraining from heterosexual intercourse during and upon completion of the study and for at least 7 months after the last dose of study drug. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. Note: Non-child-bearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases, a blood sample with simultaneous follicle-stimulating hormone \[FSH\] \> 40 mIU/mL and estradiol \< 40 pg/mL \[\< 147 pmol/L\] is confirmatory). 16. Male subjects must agree to not freeze or donate sperm starting at Screening and throughout the study period, and at least 7months after the final study drug administration. Preservation of sperm should be considered prior to enrolment in this study. 17. Female subjects must agree to not donate, or retrieve for their own use, ova from the time of Screening and throughout the study treatment period, and for at least 7 months after the final study drug administration. 18. Patients who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, post-treatment follow-up and other study procedures.
Exclusion criteria
Patients will be excluded from the study if they meet ANY of the following criteria: 1. Inability to comply with study and follow-up procedures. 2. Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor. 3. Medical history of myocardial infarction within 6 months before enrollment, symptomatic congestive heart failure (New York Heart Association Class II to IV), troponin levels consistent with myocardial infarction within 28 days prior to enrollment. 4. Corrected QT interval (QTc) prolongation to \> 470 ms (females) or \>450 ms (males) based on average of the screening triplicate12- lead ECG. 5. History of (non-infectious) interstitial lung disease (ILD) that required steroids, has current ILD, or where suspected ILD cannot be ruled out by imaging at screening. 6. Clinically significant corneal disease in the opinion of the Investigator. 7. Spinal cord compression. 8. Multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer. 9. History of severe hypersensitivity reactions to either the drug substances or inactive ingredients in the drug product. 10. History of severe hypersensitivity reactions to other monoclonal antibodies. 11. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals. 12. Patients with substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results. 13. Known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Subjects should be tested for HIV prior to enrollment if required by local regulations or institutional review board (IRB)/ethics committee (EC). 14. Female patients who are pregnant or breastfeeding or planning to become pregnant. 15. No other systemic therapy for metastatic disease including chemotherapy, immunotherapy, targeted therapy (small molecules/ monoclonal antibodies), or endocrine therapy 16. Major surgery (defined as requiring general anesthesia) or significant traumatic injury within 4 weeks of start of study drug, or patients who have not recovered from the side effects of any major surgery, or patients who may require major surgery during the study. 17. Radiotherapy within 4 weeks or limited-field palliative radiotherapy within 2 weeks prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade ≤ 1 and/or from whom ≥ 25% of the bone marrow has been previously irradiated. 18. Use of concurrent investigational agents or other concomitant anticancer therapies. 19. Use of intrathecal therapy for LMC 20. Active bleeding diathesis, previous history of bleeding diathesis, or chronic anti-coagulation treatment (the use of low molecular weight heparin is allowed as soon as it is used as prophylaxis intention). 21. Serious concomitant systemic disorder (e.g., active infection including HIV, active hepatitis, liver cirrhosis, end stage chronic renal disease) incompatible with the study (at the discretion of investigator). 22. Any of the following within 6 months of enrollment: severe/unstable angina, ongoing cardiac dysrhythmias of NCI-CTCAE v.5.0 grade 32, coronary/peripheral artery bypass graft, cerebrovascular accident including transient ischemic attack, or symptomatic pulmonary embolism. 23. Uncontrolled electrolyte disorders of NCI-CTCAE v.5.0 grade ≥ 2. 24. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (i.e. Rheumatoid arthritis, Sjogren's, sarcoidosis etc.), or prior pneumonectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) | From baseline up to 16 weeks | This outcome measure evaluates progression-free survival (PFS) in Cohort 1 over a 16-week period, using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria. |
| Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. | The proportion of patients achieving either Complete Response (CR) or Partial Response (PR) at any assessment time point, based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria |
| Overall Survival in Cohort 5 | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. | Median of OS rate for patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intra-cranial Evaluation According to RANO-BM | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. |
| Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. | The Clinical Benefit Rate (CBR) is a measure of the proportion of patients who achieve a clinically meaningful benefit from the treatment |
| Extra-cranial Evaluation According to RECIST v1.1 | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. | This outcome measure assesses the extra-cranial response of metastatic lesions outside the brain using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines. |
| Global Evaluation According to RECIST v1.1 | Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months. | The global evaluation of tumor response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. This includes classification into categories such as Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD), based on changes in tumor size and the appearance of new lesions. |
Countries
Portugal, Spain
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 •Cohort 1: HER2-positive BC with non-progressing BM (after WBRT and/or SRS and or surgery.); | 8 |
| Cohort 2 • Cohort 2: HER2-positive or HER2-low BC with asymptomatic untreated BM; | 10 |
| Cohort 3 • Cohort 3: HER2-positive BC with progressing BMs after local treatment; | 9 |
| Cohort 4 • Cohort 4: HER2-low expressing BC with progressing BMs after local treatment; | 6 |
| Cohort 5 • Cohort 5: HER2-positive or HER2-low expressing BC with LMC. | 7 |
| Total | 40 |
Baseline characteristics
| Characteristic | Cohort 1 | Cohort 3 | Cohort 4 | Cohort 5 | Total | Cohort 2 |
|---|---|---|---|---|---|---|
| Age, Continuous | 48.0 years STANDARD_DEVIATION 10.4 | 50.2 years STANDARD_DEVIATION 8.8 | 61.0 years STANDARD_DEVIATION 9.5 | 52.7 years STANDARD_DEVIATION 9.9 | 52.6 years STANDARD_DEVIATION 11 | 53.4 years STANDARD_DEVIATION 13.5 |
| ECOG 0 | 5 Participants | 6 Participants | 1 Participants | 3 Participants | 24 Participants | 9 Participants |
| ECOG 1 | 3 Participants | 3 Participants | 5 Participants | 2 Participants | 14 Participants | 1 Participants |
| ECOG 2 | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants | 0 Participants |
| Estrogen receptor status Negative | 4 Participants | 2 Participants | 3 Participants | 2 Participants | 14 Participants | 3 Participants |
| Estrogen receptor status Positive | 4 Participants | 7 Participants | 3 Participants | 5 Participants | 26 Participants | 7 Participants |
| HER2 IHC test 0 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| HER2 IHC test 1+ | 0 Participants | 0 Participants | 5 Participants | 4 Participants | 14 Participants | 5 Participants |
| HER2 IHC test 2+ | 2 Participants | 2 Participants | 1 Participants | 0 Participants | 6 Participants | 1 Participants |
| HER2 IHC test 3+ | 6 Participants | 7 Participants | 0 Participants | 3 Participants | 20 Participants | 4 Participants |
| HER2 status Indeterminate | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| HER2 status Low expressing | 0 Participants | 0 Participants | 6 Participants | 4 Participants | 16 Participants | 6 Participants |
| HER2 status Negative | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| HER2 status Positive | 8 Participants | 9 Participants | 0 Participants | 3 Participants | 24 Participants | 4 Participants |
| Hormone receptor status Negative | 1 Participants | 2 Participants | 2 Participants | 2 Participants | 10 Participants | 3 Participants |
| Hormone receptor status Positive | 7 Participants | 7 Participants | 4 Participants | 5 Participants | 30 Participants | 7 Participants |
| Measurable disease at screening No | 3 Participants | 0 Participants | 0 Participants | 4 Participants | 7 Participants | 0 Participants |
| Measurable disease at screening Yes | 5 Participants | 9 Participants | 6 Participants | 3 Participants | 33 Participants | 10 Participants |
| Number of metastatic organ sites 1 | 4 Participants | 2 Participants | 0 Participants | 1 Participants | 7 Participants | 0 Participants |
| Number of metastatic organ sites 2 | 1 Participants | 5 Participants | 0 Participants | 5 Participants | 13 Participants | 2 Participants |
| Number of metastatic organ sites 3 | 2 Participants | 1 Participants | 2 Participants | 0 Participants | 9 Participants | 4 Participants |
| Number of metastatic organ sites 4 | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 4 Participants | 2 Participants |
| Number of metastatic organ sites 5 | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 4 Participants | 0 Participants |
| Number of metastatic organ sites 6 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 2 Participants |
| Number of metastatic organ sites 7 | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Number of previous early disease treatment lines 0 | 2 Participants | 3 Participants | 1 Participants | 0 Participants | 10 Participants | 4 Participants |
| Number of previous early disease treatment lines 1 | 0 Participants | 2 Participants | 2 Participants | 0 Participants | 6 Participants | 2 Participants |
| Number of previous early disease treatment lines 2 | 1 Participants | 0 Participants | 3 Participants | 2 Participants | 8 Participants | 2 Participants |
| Number of previous early disease treatment lines 3 | 3 Participants | 3 Participants | 0 Participants | 4 Participants | 11 Participants | 1 Participants |
| Number of previous early disease treatment lines 4 | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Number of previous early disease treatment lines 5 | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants |
| Number of previous early disease treatment lines 6 | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants |
| Number of previous early disease treatment lines | 2.8 Number of previous early disease treatm STANDARD_DEVIATION 2.1 | 1.7 Number of previous early disease treatm STANDARD_DEVIATION 1.6 | 1.3 Number of previous early disease treatm STANDARD_DEVIATION 0.8 | 3.0 Number of previous early disease treatm STANDARD_DEVIATION 1 | 2.0 Number of previous early disease treatm STANDARD_DEVIATION 1.7 | 1.5 Number of previous early disease treatm STANDARD_DEVIATION 1.9 |
| Previous advanced/ metastatic disease systemic treatment lines | 8 Participants | 9 Participants | 6 Participants | 7 Participants | 40 Participants | 10 Participants |
| Previous early disease treatment Antineoplastic agents | 6 Participants | 6 Participants | 5 Participants | 7 Participants | 29 Participants | 5 Participants |
| Previous early disease treatment Endocrine therapy | 3 Participants | 5 Participants | 0 Participants | 4 Participants | 16 Participants | 4 Participants |
| Previous early disease treatment Immunosuppressants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 3 Participants | 0 Participants |
| Previous early disease treatment Therapeutic radiopharmaceuticals | 3 Participants | 3 Participants | 1 Participants | 2 Participants | 11 Participants | 2 Participants |
| Previous early disease treatment line No | 2 Participants | 3 Participants | 1 Participants | 0 Participants | 10 Participants | 4 Participants |
| Previous early disease treatment line Yes | 6 Participants | 6 Participants | 5 Participants | 7 Participants | 30 Participants | 6 Participants |
| Previous lines in advanced disease 1 | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 4 Participants | 0 Participants |
| Previous lines in advanced disease 10 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Previous lines in advanced disease 11 | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Previous lines in advanced disease 12 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Previous lines in advanced disease 13 | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants |
| Previous lines in advanced disease 2 | 2 Participants | 3 Participants | 1 Participants | 1 Participants | 8 Participants | 1 Participants |
| Previous lines in advanced disease 3 | 1 Participants | 0 Participants | 3 Participants | 0 Participants | 5 Participants | 1 Participants |
| Previous lines in advanced disease 4 | 1 Participants | 0 Participants | 2 Participants | 2 Participants | 7 Participants | 2 Participants |
| Previous lines in advanced disease 5 | 1 Participants | 3 Participants | 0 Participants | 1 Participants | 5 Participants | 0 Participants |
| Previous lines in advanced disease 6 | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants |
| Previous lines in advanced disease 7 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 4 Participants | 4 Participants |
| Previous lines in advanced disease 8 | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants | 1 Participants |
| Previous lines in advanced disease 9 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Previous systematic cancer therapy Complete or partial response | 2 Participants | 5 Participants | 1 Participants | 0 Participants | 10 Participants | 2 Participants |
| Previous systematic cancer therapy Could not be elevated | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants | 0 Participants |
| Previous systematic cancer therapy Disease progression | 2 Participants | 2 Participants | 4 Participants | 6 Participants | 19 Participants | 5 Participants |
| Previous systematic cancer therapy Endocrine therapy | 3 Participants | 4 Participants | 4 Participants | 3 Participants | 21 Participants | 7 Participants |
| Previous systematic cancer therapy LHRH agonist therapy | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 7 Participants | 4 Participants |
| Previous systematic cancer therapy Other anti-HER2 therapy | 3 Participants | 7 Participants | 0 Participants | 1 Participants | 12 Participants | 1 Participants |
| Previous systematic cancer therapy Pertuzumab | 7 Participants | 5 Participants | 0 Participants | 3 Participants | 18 Participants | 3 Participants |
| Previous systematic cancer therapy Stable disease | 2 Participants | 2 Participants | 1 Participants | 0 Participants | 8 Participants | 3 Participants |
| Previous systematic cancer therapy Trastuzumab | 7 Participants | 9 Participants | 1 Participants | 3 Participants | 23 Participants | 3 Participants |
| Previous systematic cancer therapy Trastuzumab emtansine | 4 Participants | 6 Participants | 0 Participants | 3 Participants | 15 Participants | 2 Participants |
| Progesterone receptor status Negative | 2 Participants | 2 Participants | 3 Participants | 2 Participants | 13 Participants | 4 Participants |
| Progesterone receptor status Positive | 6 Participants | 7 Participants | 3 Participants | 5 Participants | 27 Participants | 6 Participants |
| Race and Ethnicity Not Collected | — | — | — | — | 0 Participants | — |
| Sex: Female, Male Female | 8 Participants | 9 Participants | 6 Participants | 7 Participants | 40 Participants | 10 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 4 / 8 | 5 / 10 | 6 / 9 | 2 / 6 | 5 / 7 |
| other Total, other adverse events | 8 / 8 | 10 / 10 | 8 / 9 | 6 / 6 | 7 / 7 |
| serious Total, serious adverse events | 0 / 8 | 1 / 10 | 5 / 9 | 1 / 6 | 4 / 7 |
Outcome results
Primary
16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1)
This outcome measure evaluates progression-free survival (PFS) in Cohort 1 over a 16-week period, using the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.
Time frame: From baseline up to 16 weeks
Population: This outcome measure was the primary endpoint evaluated exclusively in Cohort 1. Therefore, results are only reported for the participants in this cohort.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) | With PFS at 16 weeks | 1 Participants |
| Cohort 1 | 16 Weeks PFS Per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) (Cohort 1) | Without PFS at 16 weeks | 7 Participants |
Primary
Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4)
The proportion of patients achieving either Complete Response (CR) or Partial Response (PR) at any assessment time point, based on Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria
Time frame: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
Population: This outcome measure was assessed only in Cohorts 2, 3, and 4. Therefore, data for Cohorts 1 and 5 are not included in this measure
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | No | 3 Participants |
| Cohort 1 | Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | Yes | 7 Participants |
| Cohort 3 | Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | No | 4 Participants |
| Cohort 3 | Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | Yes | 5 Participants |
| Cohort 4 | Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | No | 3 Participants |
| Cohort 4 | Objective Response Rate According RANO-BM (Cohorts 2, 3 and 4) | Yes | 3 Participants |
Primary
Overall Survival in Cohort 5
Median of OS rate for patients
Time frame: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
Population: Overall survival the primary outcome measure only in Cohort 5. Therefore, data for other cohorts are not included in this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Cohort 1 | Overall Survival in Cohort 5 | 13.3 months |
Secondary
Extra-cranial Evaluation According to RECIST v1.1
This outcome measure assesses the extra-cranial response of metastatic lesions outside the brain using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.
Time frame: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
Population: Patients that had at least one non-CNS lesion
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Extra-cranial Evaluation According to RECIST v1.1 | SD <24 weeks | 0 Participants |
| Cohort 1 | Extra-cranial Evaluation According to RECIST v1.1 | PR | 4 Participants |
| Cohort 1 | Extra-cranial Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 1 | Extra-cranial Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 1 | Extra-cranial Evaluation According to RECIST v1.1 | SD ≥24 weeks | 2 Participants |
| Cohort 3 | Extra-cranial Evaluation According to RECIST v1.1 | SD <24 weeks | 3 Participants |
| Cohort 3 | Extra-cranial Evaluation According to RECIST v1.1 | SD ≥24 weeks | 3 Participants |
| Cohort 3 | Extra-cranial Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 3 | Extra-cranial Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 3 | Extra-cranial Evaluation According to RECIST v1.1 | PR | 3 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | SD ≥24 weeks | 3 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | PR | 2 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | SD <24 weeks | 0 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | PD | 0 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | PD | 0 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | PR | 3 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | SD <24 weeks | 3 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | SD ≥24 weeks | 0 Participants |
| Cohort 4 | Extra-cranial Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 5 | Extra-cranial Evaluation According to RECIST v1.1 | SD ≥24 weeks | 5 Participants |
| Cohort 5 | Extra-cranial Evaluation According to RECIST v1.1 | SD <24 weeks | 0 Participants |
| Cohort 5 | Extra-cranial Evaluation According to RECIST v1.1 | PR | 0 Participants |
| Cohort 5 | Extra-cranial Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 5 | Extra-cranial Evaluation According to RECIST v1.1 | CR | 0 Participants |
Secondary
Global Evaluation According to RECIST v1.1
The global evaluation of tumor response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. This includes classification into categories such as Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progressive Disease (PD), based on changes in tumor size and the appearance of new lesions.
Time frame: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
Population: Patients with at least one CNS and non-CNS lesion
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Global Evaluation According to RECIST v1.1 | SD <24 | 0 Participants |
| Cohort 1 | Global Evaluation According to RECIST v1.1 | PR | 4 Participants |
| Cohort 1 | Global Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 1 | Global Evaluation According to RECIST v1.1 | SD ≥24 | 3 Participants |
| Cohort 1 | Global Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 3 | Global Evaluation According to RECIST v1.1 | SD <24 | 3 Participants |
| Cohort 3 | Global Evaluation According to RECIST v1.1 | PR | 3 Participants |
| Cohort 3 | Global Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 3 | Global Evaluation According to RECIST v1.1 | SD ≥24 | 3 Participants |
| Cohort 3 | Global Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | SD ≥24 | 4 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | SD <24 | 2 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | PR | 2 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | SD ≥24 | 1 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | PD | 0 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | PR | 2 Participants |
| Cohort 4 | Global Evaluation According to RECIST v1.1 | SD <24 | 3 Participants |
| Cohort 5 | Global Evaluation According to RECIST v1.1 | PD | 1 Participants |
| Cohort 5 | Global Evaluation According to RECIST v1.1 | SD ≥24 | 5 Participants |
| Cohort 5 | Global Evaluation According to RECIST v1.1 | SD <24 | 1 Participants |
| Cohort 5 | Global Evaluation According to RECIST v1.1 | CR | 0 Participants |
| Cohort 5 | Global Evaluation According to RECIST v1.1 | PR | 0 Participants |
Secondary
Intra-cranial Evaluation According to RANO-BM
Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
Time frame: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
Population: Patients that have at least one CNS lesion
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Intra-cranial Evaluation According to RANO-BM | SD<24w | 0 Participants |
| Cohort 1 | Intra-cranial Evaluation According to RANO-BM | CR | 2 Participants |
| Cohort 1 | Intra-cranial Evaluation According to RANO-BM | PD | 0 Participants |
| Cohort 1 | Intra-cranial Evaluation According to RANO-BM | PR | 0 Participants |
| Cohort 1 | Intra-cranial Evaluation According to RANO-BM | SD≥24w | 2 Participants |
| Cohort 3 | Intra-cranial Evaluation According to RANO-BM | SD<24w | 2 Participants |
| Cohort 3 | Intra-cranial Evaluation According to RANO-BM | SD≥24w | 1 Participants |
| Cohort 3 | Intra-cranial Evaluation According to RANO-BM | PR | 7 Participants |
| Cohort 3 | Intra-cranial Evaluation According to RANO-BM | PD | 0 Participants |
| Cohort 3 | Intra-cranial Evaluation According to RANO-BM | CR | 0 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | SD≥24w | 1 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | CR | 0 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | PR | 5 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | SD<24w | 2 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | PD | 1 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | PD | 0 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | CR | 0 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | SD<24w | 2 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | SD≥24w | 1 Participants |
| Cohort 4 | Intra-cranial Evaluation According to RANO-BM | PR | 3 Participants |
| Cohort 5 | Intra-cranial Evaluation According to RANO-BM | SD≥24w | 3 Participants |
| Cohort 5 | Intra-cranial Evaluation According to RANO-BM | SD<24w | 1 Participants |
| Cohort 5 | Intra-cranial Evaluation According to RANO-BM | CR | 1 Participants |
| Cohort 5 | Intra-cranial Evaluation According to RANO-BM | PD | 0 Participants |
| Cohort 5 | Intra-cranial Evaluation According to RANO-BM | PR | 0 Participants |
Secondary
Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1
The Clinical Benefit Rate (CBR) is a measure of the proportion of patients who achieve a clinically meaningful benefit from the treatment
Time frame: Each participant was assessed from baseline until the last tumor response evaluation, up to 16 months.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | No | 1 Participants |
| Cohort 1 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | Yes | 7 Participants |
| Cohort 3 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | No | 4 Participants |
| Cohort 3 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | Yes | 6 Participants |
| Cohort 4 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | No | 3 Participants |
| Cohort 4 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | Yes | 6 Participants |
| Cohort 4 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | Yes | 3 Participants |
| Cohort 4 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | No | 3 Participants |
| Cohort 5 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | No | 2 Participants |
| Cohort 5 | Unconfirmed Clinical Benefit Rate According to RANO-BM and RECIST v1.1 | Yes | 5 Participants |